2016
DOI: 10.1055/s-0042-110394
|View full text |Cite
|
Sign up to set email alerts
|

Role of Contrast-Enhanced Ultrasound (CEUS) in Paediatric Practice: An EFSUMB Position Statement

Abstract: The use of contrast-enhanced ultrasound (CEUS) in adults is well established in many different areas, with a number of current applications deemed "off-label", but the use supported by clinical experience and evidence. Paediatric CEUS is also an "off-label" application until recently with approval specifically for assessment of focal liver lesions. Nevertheless there is mounting evidence of the usefulness of CEUS in children in many areas, primarily as an imaging technique that reduces exposure to radiation, i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
132
0
11

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 131 publications
(146 citation statements)
references
References 130 publications
3
132
0
11
Order By: Relevance
“…The use of CEUS in children, first reported in 2002, has been addressed in an EFSUMB position statement discussing the current status of CEUS and its further development in children [63]. Currently sulphur hexafluoride gas microbubbles (SonoVue™/Lumason™, Bracco SpA, Milan) has been approved in the United States by the Food and Drug Administration (FDA) as Lumason™ for characterising focal liver lesions in children ["Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions"] and vesico-ureteral reflux.…”
Section: Paediatric Patients and Newbornsmentioning
confidence: 99%
“…The use of CEUS in children, first reported in 2002, has been addressed in an EFSUMB position statement discussing the current status of CEUS and its further development in children [63]. Currently sulphur hexafluoride gas microbubbles (SonoVue™/Lumason™, Bracco SpA, Milan) has been approved in the United States by the Food and Drug Administration (FDA) as Lumason™ for characterising focal liver lesions in children ["Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions"] and vesico-ureteral reflux.…”
Section: Paediatric Patients and Newbornsmentioning
confidence: 99%
“…Comments on EFSUMB guidelines have been published as well [18,32,33,[36][37][38][39][40][41][42][43]. Most recently we refer to the Pediatric Position paper on the use of CEUS [44].…”
Section: Historymentioning
confidence: 99%
“…Update CEUS non-liver Previous contrast enhanced ultrasound (CEUS) documents from the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) have been published encompassing hepatic and non-hepatic applications with a statement on CEUS use in paediatric applications [44]. The CEUS non-liver update reflects the current applications in non-hepatic CEUS and updates the previous EFSUMB guidelines published in 2012 [13].…”
Section: Update Elastography Liver Guidelinesmentioning
confidence: 99%
“…use of ultrasonography contrast agents is still "off-label" for the paediatric population in Europe, it has been widely used with documented safety and accuracy. 1,9,10 A recent and important development has been the approval by the Food and Drug Administration of the use of CEUS for liver examination in children in the USA, 11 and this will alter application not only in the USA but also across the world. Ultrasound practitioners should be mindful that many drugs are used "off-label" in children, and this is not prohibited by medical regulatory authorities.…”
Section: Introductionmentioning
confidence: 99%